• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Moderna’s (MRNA) New mRNA-4200 Trial Quietly Rebalance Its Long-Term Oncology Risk Profile?

    Simply Wall St·07/18/2026 06:27:29
    Listen to the news
    • Earlier this month, Moderna announced it had dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an mRNA-based, tumor-targeted cancer antigen therapy being tested with checkpoint inhibitor treatment in adults with advanced solid tumors under its collaboration with Immatics.
    • This early-stage oncology milestone underscores Moderna’s effort to extend its mRNA platform beyond infectious diseases into cancer, adding a new dimension to how investors may think about the company’s long-term pipeline mix and clinical risk profile.
    • We’ll now explore how the initiation of the mRNA-4200 Phase 1 cancer trial may influence Moderna’s existing investment narrative and risk balance.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Moderna Investment Narrative Recap

    To own Moderna today, you need to believe its mRNA platform can evolve from a COVID-dependent story into a broader vaccines and oncology business while eventually narrowing sizeable losses. The new Phase 1 mRNA-4200 cancer trial and the appointment of seasoned financial executive Michael McDonnell to the board do not materially change the near term focus, which still centers on influenza and RSV vaccine milestones and the risk that respiratory revenues remain volatile and highly seasonal.

    The most relevant recent update alongside the mRNA-4200 news is the FDA advisory committee’s unanimous support for Moderna’s mFlusiva influenza vaccine for adults 50 and older. Together, early oncology progress and a potential first mRNA flu approval highlight how Moderna is trying to rebalance its catalyst mix toward both seasonal and non seasonal products, even as revenue remains concentrated in a few vaccines and the company continues to post sizeable net losses.

    Yet behind this progress, investors should also be aware that continued pressure on vaccine pricing could...

    Read the full narrative on Moderna (it's free!)

    Moderna's narrative projects $3.7 billion revenue and $695.7 million earnings by 2029. This requires 18.2% yearly revenue growth and about a $3.9 billion earnings increase from -$3.2 billion today.

    Uncover how Moderna's forecasts yield a $44.25 fair value, a 28% downside to its current price.

    Exploring Other Perspectives

    MRNA 1-Year Stock Price Chart
    MRNA 1-Year Stock Price Chart

    While consensus sees faster revenue expansion, the most bearish analysts before this news expected only about 3.2% annual growth and unprofitability to persist, so you are weighing very different futures.

    Explore 6 other fair value estimates on Moderna - why the stock might be worth less than half the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
    • Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

    Ready To Venture Into Other Investment Styles?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.